Biopharma Daily Stock Updates - 07/13/21
$XBI $129.63 -1.7%
Pipeline Updates
$SCPH +7.3% scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study. source
$JAZZ -1.2% Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021. source
$HEPA -15.3% Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved. source
$RDHL -2.1% RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans. source
$GLTO -3.8% Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis. source
$MBRX -0.3% Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia. source
$TFFP +0.4% TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder. source
$SBBP -2.4% Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve. source
$GNCA -1.0% Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy. source
$LVTX -1.1% LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies. source
$HCM +1.7% First Commercial Sale of ORPATHYS® in China Triggering a US$25 million Milestone Payment from AstraZeneca. source
$PLXP +27.2% PLx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August. source
$IKNA -16.5% Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 on July 15. source
$INMB +12.7% INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS). source
$GALT -15.2% On 7/9/21 Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer. source
Financial Updates
$CLRB -3.5% Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc. source
$PCRX -2.1% Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021. source
$KALV -3.3% KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results. source
$IONS -2.5% Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology. source
$BCYC +4.1% Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics. source
$ISEE +4.6% IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock. source
Posted by FS
Comments